Biblio
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation. Bone Marrow Transplant. 2023.
Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2023.
Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message?. Acta Haematol. 2020:1-2.
. Incidence of blast phase in myelofibrosis according to anemia severity. EJHaem. 2023;4(3):679-689.
.
RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA. Hematol Oncol. 2020.
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021;385(3):228-238.
Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2020.
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. Blood Adv. 2019;3(21):3196-3200.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.